Comments to White House OSTP on Modernizing Biotechnology Regulations

In comments to the White House Office of Science and Technology Policy, ITIF's Val Giddings argues there is no relationship between the degree of regulatory scrutiny a biotechnology product receives and the degree of hazard it represents. To enable and encourage innovation, the administration should restore that balance to the U.S. framework for biotechnology regulation.